4immune Therapeutics, Inc. has secured the rights to a novel technology founded out of MGH/BU that is potentially curative for a broad range of T cell-mediated autoimmune disorders. Our technology leverages the constructs of FDA- approved CAR T cell therapies that have been used to successfully treat B cell cancers, with the addition of a proprietary ligand that targets and kills the autoreactive T cells responsible for specific autoimmune disorders. The company's lead therapeutic will treat early-stage type 1 diabetes, destroying disease-causing T cells to stabilize glucose levels and prevent further islet cell damage. There is presently no cure for type 1 diabetes which impacts 64,000 people in the U.S. each year. Sufficient data has been generated to support an INTERACT meeting with the FDA in preparation for IND submission for a phase I trial for early-stage T1D in patients 18 years and over. The company has attracted an experienced management team, scientific leaders in the T1D field and strong partners (such as Dark Horse Consulting) and is in advanced discussions with ElevateBio, a leading cell manufacturing company in the cell therapy field, for process development and manufacturing of the clinical product.

At Cerberus Therapeutics we are pioneering an alpaca-derived single domain antibody fragment (VHH)-based platform to create novel therapeutics capable of immune modulation. Our initial programs focus on developing therapies for several autoimmune disorders, as well as tolerance against immune reactions to Adeno-Associated Virus ("AAV") vectors. By incorporating genetic and biochemical protein modification strategies, we have shown that just a single dose of these engineered VHHs achieve robust in vivo efficacy in preclinical mouse models of several autoimmune diseases including multiple sclerosis, type I diabetes, and rheumatoid arthritis, both prophylactically and therapeutically. The intellectual property in our possession covers the development and application of these engineered VHHs for treating autoimmune diseases and other immune-mediated conditions.

HDAX Therapeutics is on a mission to revolutionize the treatment of neurological and cardiovascular diseases driven by microtubule dysfunction through our best-in-class, disease-modifying therapeutics. By targeting the disease driver HDAC6 through our novel, proprietary 2-site binding mechanism, we aspire to target the root of diseases, to create solutions that bring lasting benefits, enabling patients to thrive and live life to the fullest.

HitchBio develops red blood cell transfusion based solutions utilizing Cellgrip technology to affix and deliver diverse therapeutics with increased delivery efficiency to tissue. This approach allows for improved tissue targeting (lungs via intravenous administration, other organs via intra-arterial administration) and evasion of the immune system.

We are Materialize Bio, the groundbreaking medical device company revolutionizing the field of implants. We recognize the limitations of current commercially available implants, which fail to meet various clinical needs due to material and manufacturing constraints. But we have the solution. Imagine implants with tunable degradation, precisely aligning with soft tissue healing within days or months. Or implants that can degrade 'on command' when they are finished serving their purpose. Our 3D natural polymer-based implants have the potential to prevent post-surgical complications like infections and scar formation, eliminating the need for additional surgeries. What sets us apart is our ability to harness the unique properties of natural biopolymers, which possess remarkable antimicrobial, biocompatibility, and degradation features. While others have been able to create 2D films or threads, our core team has developed intellectual property that allows Materialize to manufacture and scale these materials into complex 3D structures efficiently and reproducibly. But that's not all. Our implants can also incorporate functional drug delivery, overcoming the challenges of incorporating drugs into synthetic or biologic materials. We are equipped with innovative methods to enable drug release within our 3D implants, allowing targeted and controlled delivery that offers potential to enhance patient outcomes.

At NeuroBionics, we are revolutionizing the field of bioelectronic interfacing. We are driven by a mission to develop the next generation of implantable devices that seamlessly interface with the human body, unlocking new possibilities in healthcare and paving the way for a healthier future. We are leveraging a decade of research in microscopic fiber technology developed at MIT to create minimally invasive implantable devices, capable of recording and modulating activity in the body with unparalleled precision and versatility. Our vision is to leverage the power of our flexible fibers to bring bioelectronic medicine into the mainstream. We believe in the potential of bioelectronic interfaces to revolutionize the treatment of various medical conditions by directly interfacing with the body's intricate neural networks. Starting with neuroscience

SynBio Therapeutics Platform out of UCLA, developing First and Best In Class Therapeutics for Massive Cardiometabolic Unmet Needs. We aim to positively affect the lives and health of 2 Billion people worldwide. We develop a first-in-class therapeutic and a brand new modality, with our SynBio platform.

Venova Technologies is a women-led and minority-led medical device startup company, developing the first non- hormonal female birth control device designed to be highly effective, long-acting, and side-effect-free. Half of the 6.6 million pregnancies in the US each year are unintended, disproportionately affecting women of color, women in low- income settings, and adolescents. While contraception is effective at preventing pregnancy, half of women in the US will stop using their birth control due to side effects. Forty percent of women prefer not to use hormonal contraception, but there are few available options. The copper intrauterine device (IUD) is the only non-hormonal contraceptive device in the US that is highly effective, but it has a high incidence of unacceptable side effects, such as heavier and painful menstrual bleeding. Other non-hormonal methods such as condoms and spermicides have high failure rates. We are developing an innovative solution to directly address this clinical unmet need for additional highly effective, non- hormonal contraceptive options for women.